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Background: Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis (RENEW) was a 5-year, phase IV
study in which the safety of Mitoxantrone was monitored in a patient cohort from the United States (US). The objective
of the study was to evaluate the long-term safety profile of Mitoxantrone in patients with secondary progressive
multiple sclerosis (SPMS), progressive relapsing multiple sclerosis (PRMS), and worsening relapsing-remitting multiple
sclerosis (RRMS).
Methods: Overall, 509 patients (395 SPMS, 81 worsening RRMS, 33 PRMS) were enrolled and treated at 46 multiple
sclerosis (MS) treatment centers located in the US. Patients received Mitoxantrone in accordance with the package
insert every 3 months. During the treatment phase, patients received laboratory workups and cardiac monitoring every
3 months and then annually for a total of 5 years.
Results: Five hundred and nine subjects were enrolled in this trial and received at least one infusion of Mitoxantrone.
Overall, 172 (33.8%) completed the 5-year trial (i.e., participated for 5 years ± 3 months [treatment + follow-up]); 337
(66.2%) did not complete the 5-year trial. Annual follow-up data were available for 250 of 509 enrolled patients. Left
ventricular ejection fraction reduction under 50% was reported in 27 (5.3%) patients during the treatment phase
(n = 509) and 14 (5.6%) patients during the annual follow-up phase (n = 250). Signs and symptoms of congestive heart
failure were observed in 10 (2.0%) patients (six during treatment phase and four during the annual follow-up phase).
Post-hoc analyses of the risk for cardiotoxicity outcomes revealed that cumulative dose exposure is the primary risk
factor associated with the risk of cardiac toxicity with Mitoxantrone. Therapy-related leukemia was reported in three
(0.6%) patients who received total cumulative Mitoxantrone doses of 73.5 mg/m2, 107.3 mg/m2, and 97.1 mg/m2
respectively. During the treatment phase, persistent amenorrhea developed in 22% (28/128) of women with regular
menses and 51% (25/49) of women with irregular menses at baseline. During the annual follow-up phase, persistent
amenorrhea developed in 5% (4/73) of women with regular menses at baseline.
Conclusion: RENEW results are consistent with the known safety profile of Mitoxantrone, and provide additional
long-term safety data for Mitoxantrone in MS patients.Background
Mitoxantrone is a synthetic anthracenedione agent origin-
ally developed for the treatment of cancer. Subsequent
preclinical studies also demonstrated the immunosuppres-
sive properties of Mitoxantrone [1-3], which eventually
led to its clinical investigation in patients with multiple
sclerosis (MS) [4,5]. Based on efficacy and safety results
from two randomized clinical trials [4,5], Mitoxantrone* Correspondence: vrivera@bcm.edu
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reproduction in any medium, provided the orwas approved for the treatment of secondary progressive
MS (SPMS), progressive relapsing MS (PRMS), and wors-
ening relapsing-remitting MS (RRMS) in the United States
(US) and Europe.
The use of Mitoxantrone in patients with MS, however,
is associated with significant risks that include, among the
more serious concerns, cardiotoxicity [6-15], treatment-
related leukemia [16-32], and amenorrhea [33]. At present,
the risk factors contributing to these toxicities are not
completely understood. The main objective of the current
report is to present the long-term safety data from thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Multiple Sclerosis (RENEW) Study. Results from this
phase IV study provide additional data on the long-term
safety of Mitoxantrone in MS patients, and offer some




RENEW was a multicenter, prospective, open-label, ob-
servational phase IV study monitoring the safety and tol-
erability of Mitoxantrone. From 17 October 2000 until
15 July 2008, 509 patients were enrolled and treated at
46 MS treatment centers located in the US.
Patients aged 18–65 years with clinically defined or a
laboratory-supported diagnosis of SPMS, PRMS, or wors-
ening RRMS were included in the study if they had a plate-
let count in excess of 100,000 cells/μL and a granulocyte
count in excess of 2,000 cells/μL. Patients were excluded
from the study if they presented with cardiac risk factors,
including a history of congestive heart failure (CHF) or left
ventricular ejection fraction (LVEF) <50% of normal.
Patients were treated with commercially available
Mitoxantrone in accordance with the package insert (i.e.,
12 mg/m2 as a 5–15 minute intravenous [IV] infusion).
Doses were administered approximately every 3 months
until a cumulative dose of 140 mg/m2 was reached, unless
the patient or physician chose to discontinue or interrupt
therapy or there was an adverse event (AE) that prevented
further therapy. All enrolled patients, regardless of dur-
ation of therapy, were to be followed until the end of their
5-year trial participation period.
All participating investigators obtained local institutional
review board approval prior to their initiation of the study,
and all patients provided written informed consent before
enrolment.
This study was conducted in compliance with the ethical
principles enunciated in the World Medical Association's
Declaration of Helsinki, Ethical Principles for Medical Re-
search Involving Human Subjects.
Study assessments
Patients were medically evaluated before treatment ini-
tiation, including the assessment of their Expanded Dis-
ability Status Scale (EDSS) score. Patients were assessed
every 3 months during the treatment phase and then
annually, for a total of 5 years. All enrolled subjects
were to be followed to the end of their 5-year trial par-
ticipation period.
Cardiovascular endpoints included LVEF (measured
using echocardiogram or a multiple gated acquisition scan),
symptoms of CHF, and cardiac-related serious AEs (SAEs).
Assessments of LVEF and CHF were performed at baseline,
before each infusion, and annually after treatmentdiscontinuation or completion; SAEs were reported as they
occurred.
At baseline, women were classified as having regular,
irregular, or absent menses. Women with regular or ir-
regular menses were monitored for the development of
on-study persistent amenorrhea (defined as the absence of
menses on at least two consecutive treatment visits that
did not subsequently return during the course of the
study) or transient amenorrhea (resumption of menses
after absence on ≥2 consecutive treatment visits). Women
with absent menses at baseline were monitored for re-
sumption of menses (≥1 report of menses on-study).
Statistical methods
Demographic, baseline, cumulative dose, and LVEF data
were summarized by type of MS using descriptive statis-
tics. Frequencies with 95% confidence intervals (CIs) were
used to evaluate the incidence of SAEs, symptomatic CHF,
abnormal LVEF (<50%), and serious infections. The inci-
dence of clinical relapses, skipped and missed doses, ab-
normal laboratory values and concomitant medications
were also summarized. For female patients, menstrual
status was tabulated (regular, irregular, absent).
Post-hoc analyses
To assess the factors potentially contributing to cardio-
toxicity, post-hoc analyses were conducted in all patients
receiving Mitoxantrone alone or concomitantly with other
medications during the RENEW study. Patients with and
without cardiac events were included in the analysis. Pres-
ence of cardiac events was defined as LVEF <50%, clinically
significant drop in LVEF as indicated by a 10% decrease
from baseline, cardiac SAE, or signs or symptoms of CHF
requiring hospitalization or other treatment.
Poisson and logistic regression models were used to de-
termine the significance of the effects of potential contrib-
uting factors on cardiotoxicity risk. A Fisher’s exact test was
used to evaluate the effects of concomitant medication.Results
Study cohort
Demographics, baseline characteristics, and study comple-
tion statistics for RENEW are shown in Table 1. Data were
available for all 509 patients during the treatment phase.
Long-term follow-up data were available for 250 (49%) pa-
tients (not all patients in the follow-up phase completed
the study). In general, the majority of patients were female
(67.6%); mean age at baseline was 46 years (range 19–68).
Most patients (77.6%) were diagnosed with SPMS. The
mean baseline LVEF was 62%. Median baseline EDSS
score was 6 (range 0–9) and median times since onset of
MS and MS diagnosis were 11.8 years (range 0.4–45.3)
and 8.6 years (0.0–39.9), respectively.
Table 1 Patient characteristics
Characteristic Overall Worsening PRMS SPMS
RRMS
At baseline
Patients enrolled,a n (%) 509 (100.0) 81 (15.9) 33 (6.5) 395 (77.6)
Mean age, years (range) 46 (19–68) 40 (19–63) 47 (30–64) 47 (25–68)
Women,% 67.6 77.8 54.5 66.6
White,% 88.6 85.2 87.9 89.4
History of MS, n 506 80 32 394
Median EDSS score (range) 6.0 (0.0–9.0) 4 (1.0–8.0) 6.0 (1.5–8.5) 6.5 (0.0–9.0)
Median years since onset (range) 11.8 (0.4–45.3) 8.0 (0.4–29.2) 11.5 (0.6–34.5) 13.0 (0.6–45.3)
Median years since diagnosis (range) 8.6 (0.0–39.9) 4.8 (0.0–24.6) 7.3 (0.1–26.5) 9.3 (0.1–39.9)
Median years since most recent relapse (range) 0.4 (0.0–20.3) 0.2 (0.0–2.4) 0.2 (0.0–4.6) 0.5 (0.0–20.3)
Patients with no prior treatment for MS, n (%) 16 (3.1) 3 (3.7) 2 (6.1) 11 (2.8)
Women with regular menses, n (%) 128 (37.2) 34 (54.0) 7 (38.9) 87 (33.1)
Cardiac, n 505 81 32 392
Mean LVEF,% (range) 62 (50–83) 62 (50–83) 63 (52–79) 62 (50–83)
Study completion, n 509 81 33 395
Patients who did not complete 486 (95.5) 74 (91.4) 32 (97.0) 380 (96.2)
Mitoxantrone treatment,b n (%)
Did not complete 5-year study,c n (%) 320 (62.9) 46 (56.8) 27 (81.8) 247 (62.5)
Completed 5-year study,c n (%) 166 (32.6) 28 (34.6) 5 (15.2) 133 (33.7)
Patients who completed 23 (4.5) 7 (8.6) 1 (3.0) 15 (3.8)
Mitoxantrone treatment,b n (%)
Did not complete 5-year study,c n (%) 17 (3.3) 5 (6.2) 1 (3.0) 11 (2.8)
Completed 5-year study,c n (%) 6 (1.2) 2 (2.5) 0 (0) 4 (1.0)
EDSS=Expanded Disability Status Scale; LVEF=left ventricular ejection fraction;MS=multiple sclerosis; PRMS=progressive relapsing multiple sclerosis;
RENEW=Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis; RRMS=relapsing remitting multiple sclerosis; SPMS=secondary progressive
multiple sclerosis.
aPatients with validated data who have received at least one dose of Mitoxantrone.
bPatients reaching a cumulative dose of 132 mg/m2 or greater are considered to have completed treatment.
cPatients participating in the study for 5 years ± 3 months are considered to have completed RENEW.
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study. Of these patients, six (1.2%) completed full treatment
with Mitoxantrone (i.e., reached a cumulative dose of
132 mg/m2 or greater) while 166 (32.6%) patients did not.
The mean duration of Mitoxantrone therapy was 1.5 years
(range 0.0–4.9 years). The majority of subjects were in the
trial for over 42 months (n = 263, 51.7%) while 57 (11.2%)
patients were in the study for ≤12 months. The mean cu-
mulative dose per patient was 69.8 mg/m2 (range 8.0–
148.6 mg/m2). Patients received a mean of six infusions
(range 1–18 infusions) during the study period (Figure 1).
Doses <10 mg/m2 were received by 121 (24%) patients and
accounted for 517 (16%) of all infusions administered dur-
ing the study period. Overall, 361 out of 509 (71%) received
concomitant therapy, of which the most common were
glatiramer acetate (25.3%), methylprednisolone IV (21.0%),
interferon beta-1a intramuscularly (20.6%), interferon beta-
1b (14.9%), interferon beta-1a subcutaneous (11.8%), andoral prednisone (5.7%). Treatment discontinuation was
reported in 486 (95.5%) patients (Table 2). The most fre-
quently cited reasons for treatment discontinuation were
physician decision (28.7%) and patient’s request (25.9%).
Cardiovascular AEs
Ten patients experienced CHF during the trial (six during
the treatment phase and four during the annual follow-up
phase). The median latency of CHF events from the first
dose of Mitoxantrone was 24.2 months (range 9.5–
35.6 months) (Figure 2). Twenty-seven of 509 patients
(5.3%) during the treatment phase and 14 of 250 patients
(5.6%) during the annual follow-up phase experienced
LVEF test results that decreased to below 50%. The me-
dian latency of LVEF reductions below 50% from the first
dose of Mitoxantrone during the treatment phase was
29 months (range 13.3–44.6 months) (Figure 2). Twenty-
five cardiac-related SAEs were reported among 22 of 509
Figure 1 Distribution of the number of infusions of Mitoxantrone*. *Includes only patients who received at least one dose of Mitoxantrone.
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common being ejection fraction decreased (12 patients,
2.4%; 12 events) (Table 3). During the annual follow-up
phase, five cardiac-related SAEs were reported in four of
250 patients (1.6%). These events included ejection fraction
decreased (two patients, 0.8%; two events), cardiomyopathy
(two patients; 0.8%; two events), and tachycardia (one pa-
tient, 0.4%; one event) (Table 3).Table 2 RENEW treatment discontinuations
Ov
Patients enrolleda
Discontinued treatment, n (%) 486
Deathb 4
Other adverse event 14
Physician decision 146
Reached maximum cumulative dose (≥140 mg/m2)c 23
Lack of efficacy 16
Lost to follow-up 40
LVEF <50% 25




CHF=congestive heart failure; LVEF=left ventricular ejection fraction; MS=multiple sc
Evaluate Novantrone Effects in Worsening Multiple Sclerosis; RRMS=relapsing-remit
aPatients with validated data who have received at least one dose of Mitoxantrone.
bEight additional patients died following discontinuation; the reasons for discontinu
request (n = 2); LVEF <50% (n = 1); and clinically significant reduction in LVEF/CHF (n
cIncludes patients who have reached a cumulative dose of at least 132 mg/m2.
dClinical significance determined by the study site investigator.In response to a Food and Drug Administration request,
additional post-hoc analyses of the RENEW study were
completed. These analyses were intended to provide valid
estimates of the risk for cardiotoxicity outcomes in the
RENEW study, and to examine the impact of potential ex-
planatory factors on cardiotoxicity risk among this cohort
of MS patients. Results showed that the cumulative dose of
Mitoxantrone is the primary risk factor associated witherall Type of MS
Worsening PRMS SPMS
RRMS
509 81 33 395
(95.5) 74 (91.4) 32 (97.0) 380 (96.2)
(0.8) 1 (1.2) 0 3 (0.8)
(2.8) 2 (2.5) 2 (6.1) 10 (2.5)
(28.7) 28 (34.6) 6 (18.2) 112 (28.4)
(4.5) 5 (6.2) 1 (3.0) 17 (4.3)
(3.1) 0 2 (6.1) 14 (3.5)
(7.9) 3 (3.7) 2 (6.1) 35 (8.9)
(4.9) 0 1 (3.0) 24 (6.1)
(2.0) 2 (2.5) 2 (6.1) 6 (1.5)
(25.9) 24 (29.6) 11 (33.3) 97 (24.6)
(19.3) 16 (19.8) 6 (18.2) 76 (19.2)
(0.2) 0 0 1 (0.3)
lerosis; PRMS=progressive relapsing multiple sclerosis; RENEW=Registry to
ting multiple sclerosis; SPMS=secondary progressive multiple sclerosis.
ation of Mitoxantrone treatment were: physician discretion (n = 4); patient
= 1).
Figure 2 Latency of CHF events and LVEF <50% events. CHF=congestive heart failure; CV=cardiovascular; LVEF=left ventricular ejection fraction.
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higher in patients with cardiac events (n = 97; 93.9 mg/m2)
than in those without cardiac events (n = 412; 63.7 mg/m2).
The dose-dependent, cardiotoxic effect of Mitoxantrone
was confirmed to be statistically significant when cumu-
lative dose was analyzed as a dichotomous covariate
(Figure 3). Among patients with cardiac events, 74.2%
of patients received doses >75 mg/m2 compared with
25.8% of patients who received ≤75 mg/m2 (p < 0.0001).
Though not statistically significant, there were consistent
trends suggesting higher cardiac toxicity in various popu-
lations, including: higher age group; SPMS vs relapsing
MS; longer disease duration; higher EDSS; use of con-
comitant immunosuppressants and/or disease-modifying
drugs (see Additional file 1). Lastly, use of MitoxantroneTable 3 Summary of cardiac-related SAEs
SAE, n (%) Overall
(N = 509)
Any cardiac event 25a (4.9)
Reduced LVEF 14 (2.8)
Myocardial infarction 4 (0.8)
Cardiomyopathy 5 (1.0)
Congestive heart failure 2 (0.4)
Cardiorespiratory arrest 1 (0.2)
Mitral valve incompetence 1 (0.2)
Tachycardia 2 (0.4)
Ventricular hypokinesia 1 (0.2)
LVEF=left ventricular ejection fraction; SAE=serious adverse event.
aOne patient had an SAE in both the treatment and follow-up phase.and previous or concomitant use of oral Methotrexate was
significantly associated with cardiotoxicity risk and there
was a trend toward significance when oral Methotrexate
was used after study entry (Figure 4).Hematologic effects
Leukemia was reported in three patients, resulting in an in-
cidence rate of 0.6%. Among these cases, two occurred dur-
ing the annual follow-up phase of the study. In case 1, the
patient was diagnosed with acute myelogenous leukemia
(AML), M4 type in 2004, approximately 30 months follow-
ing the first dose of Mitoxantrone (total cumulative dose
was 73.5 mg/m2). The patient received chemotherapy and
achieved remission in November 2005. As of January 2008,Treatment phase Annual follow-up
(n = 509) phase (n = 250)
22 (4.3) 4 (1.6)
12 (2.4) 2 (0.8)
4 (0.8) 0




1 (0.2) 1 (0.4)
1 (0.2) 0
Table 4 Association between cardiotoxicity risk and cumulative dose
Cumulative dose Overall Patients with Patients without p
valueacategory, n (%) (N = 509) cardiac events cardiac events
(n = 97) (n = 412)
>0 and ≤35 mg/m2 82 (16.1) 6 (6.2) 76 (18.4) REF
>35 and ≤75 mg/m2 204 (40.1) 19 (19.6) 185 (44.9) >0.05
>75 and ≤105 mg/m2 149 (29.3) 33 (34.0) 116 (28.2) <0.01
>105 mg/m2 74 (14.5) 39 (40.2) 35 (8.5) <0.0001
aFrom Poisson and logistic regression models; pairwise comparisons of cumulative dose categories are presented with lowest dose category as reference.
REF=reference value.
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tient was diagnosed with chronic phase chronic myeloid
leukemia (CML) in 2006, approximately 63 months follow-
ing the first dose of Mitoxantrone (total cumulative dose
was 107.3 mg/m2). In June 2006 (exact date unknown), the
patient began therapy with imatinib. On 28 June 2006, the
patient’s white blood cell count fell from 30,000 to 18,900
and the event was not resolved. No additional informa-
tion regarding the outcome of case 2 is available at this
time. Case 3 involved a patient who developed acute
promyelocytic leukemia (APL). The total cumulative
dose of Mitoxantrone was 97.1 mg/m2 (first dose on 29
December 2000 and last dose on 3 October 2003). De-
tails regarding the date of APL diagnosis and outcome
were not included in the initial report. Three requests
for information were made to the trial site to obtain de-
tails surrounding the diagnosis of APL (including path-
ology reports) and subsequent treatment and outcome,
but no further information on the patient’s leukemia
was obtainable.Figure 3 Association between cardiotoxicity risk and cumulative dose
or symptoms of CHF requiring hospitalization or other therapy, with an LVEF
indicated by a 10% decrease from baseline. CHF=congestive heart failure; LVEAmenorrhea
At baseline, 128 women reported regular menses. During
the treatment phase of the study, 28 (22%) women devel-
oped persistent amenorrhea having received a mean cu-
mulative dose of 52.1 mg/m2, and five (4%) women
developed transient amenorrhea having received a mean
cumulative dose of 70.5 mg/m2. During the annual follow-
up phase, 73 women reported regular menses at baseline;
of these women, four (5%) developed persistent amenor-
rhea while one (1%) developed transient amenorrhea.
Forty-nine women reported irregular menses at baseline;
of these women, 25 (51%) developed persistent amenor-
rhea having received a mean cumulative dose of 38.2 mg/
m2during the treatment phase of the study, and one (2%)
developed transient amenorrhea having received a cumula-
tive dose of 59 mg/m2. During the annual follow-up phase,
no patients with irregular menses at baseline developed
persistent amenorrhea while only one of 26 women (4%)
developed transient amenorrhea. During the treatment
phase of the study, resumption of menses was reported by. Cardiac events includes patients with reported cardiac SAEs, with signs
decrease to 50% of baseline, or with a clinically significant drop in LVEF as
F=left ventricular ejection fraction; SAE=serious adverse event.
Figure 4 Risk of cardiotoxicity with prior and/or concomitant Methotrexate therapy. Cardiac events includes patients with reported cardiac
SAEs, with signs or symptoms of CHF requiring hospitalization or other therapy, with an LVEF decrease to 50% of baseline, or with a clinically
significant drop in LVEF as indicated by a 10% decrease from baseline. CHF=congestive heart failure; LVEF=left ventricular ejection fraction;
MTX=Methotrexate; SAE=serious adverse event.
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23 mg/m2 and had reported an absence of menses at base-
line; no patients with absent menses at baseline resumed
menses during the observational phase.AEs and deaths
During the treatment phase, a total of 143 SAEs were
reported in 88 patients (see Table 5 and Additional file 2).
The most commonly reported SAE during the treatment
phase was decreased ejection fraction (12 patients, 2.4%; 12
events, 11 of which were considered treatment related).
During the annual follow-up phase of the study, 23 patients
experienced 39 SAEs (see Table 6 and Additional file 2).
The most commonly reported SAE during the annual
follow-up phase was urinary tract infection (UTI) (three pa-
tients, 1.2%; four events).
A total of 60 cases of serious infection were reported
(n = 41) during the study (see Additional file 3). During the
treatment phase, 38 (7.5%) patients had 47 infectious SAEs,
with the most common being UTI (11 patients, 2.2%; 13
events). During the annual follow-up phase, eight (3.2%)
patients had 13 serious infectious events, with the most
common being UTI (three patients, 1.2%; four events).
Twelve deaths were reported during the study (Table 7).
Eight of the 12 deaths occurred during the treatment
phase. Median EDSS score was 7 (range 4–9); median cu-
mulative dose was 81.9 mg/m2 (range 11.1–119.4 mg/m2).
Events accounting for at least two deaths included: infec-
tion (n = 3; pneumonia, acute meningitis, and septic
shock); cardiac-related SAEs (n = 2), and pulmonary em-
bolism (n = 2).Discussion
The cardiotoxic risk associated with Mitoxantrone in pa-
tients with MS is well-documented [6-15]. In 2010, the
Therapeutics and Technology Assessment (TTA) Subcom-
mittee of the American Academy of Neurology reviewed all
articles and abstracts published before July 2009 containing
‘Mitoxantrone’ and ‘multiple sclerosis’ [25]. Investigators
identified and consolidated 11 class III evidence studies to
analyze cardiotoxicity. From this analysis (n = 716), de-
creased LVEF was estimated to be approximately 12% while
the risk of CHF was estimated to be approximately 0.4%;
the number needed to harm (NNH) for left ventricular dys-
function was eight. The authors cautioned, however, that
these estimates are a general approximation given that dos-
ing regimens and cardiac testing varied among the different
treatment centers. More recently, Le Page and colleagues
published final results from a 5-year prospective study in a
French cohort of 802 MS patients [33]. The final mean cu-
mulative dose of Mitoxantrone in this study was 78 mg/m2,
with 18.5% of patients receiving more than 100 mg/m2; the
mean follow-up was 6.7 years. There was one case of acute
CHF out of the 802 total patients (0.1%). Of 794 patients
who received LVEF assessment testing, 39 (4.9%) experi-
enced an asymptomatic decrease of LVEF <50%. Decreased
LVEF <50% was reversible in 27 (69.2%) patients, persistent
in 11 (28.2%) patients, and only observed on the last scan
in one patient (2.6%) remaining clinically symptomatic.
Analysis of risk factors did not reveal any factor predictive
of the occurrence of a LVEF decrease.
In the RENEW trial, the mean cumulative dose of
Mitoxantrone was 69.8 mg/m2 and patients received treat-
ment for an average of 1.5 years. During the treatment
Table 5 Treatment-related SAEs during RENEW
treatment phase
SAE Treatment phase (n = 509)
Number of treatment-related events
Possible Probable Total
Decreased ejection fraction 1 10 11
Urinary tract infection 1 3 4
Cardiomyopathy 0 3 3
Febrile neutropenia 1 2 3
Leukopenia 0 3 3
Pneumonia 0 3 3
Congestive heart failure 0 2 2
Cellulitis gangrenous 0 1 1
Herpes zoster 0 1 1
Upper respiratory tract infection 0 1 1
Urosepsis 0 1 1
Ventricular hypokinesia 0 1 1
Myocardial infarction 2 0 2
Nausea 2 0 2
Sepsis 2 0 2
Septic shock 2 0 2
Vomiting 2 0 2
Abortion incomplete 1 0 1
Cellulitis 1 0 1
Deep vein thrombosis 1 0 1
Dizziness 1 0 1
Fungal skin infection 1 0 1
Hydronephrosis 1 0 1
Localized infection 1 0 1
Lung infection 1 0 1
Meningitis 1 0 1
Pituitary tumor 1 0 1
Pulmonary embolism 1 0 1
Varicella 1 0 1
SAE=serious adverse event; RENEW=Registry to Evaluate Novantrone Effects in
Worsening Multiple Sclerosis.
Table 6 Treatment-related SAEs during RENEW annual
follow-up phase
SAE Annual follow-up phase (n = 250)
Number of treatment-related events
Possible Probable Total
Decreased ejection fraction 0 2 2
Acute myeloid leukemia 0 1 1
Pneumonia 0 1 1
Anorexia 1 0 1
Cardiomyopathy 1 0 1
Tachycardia 1 0 1
Chronic myeloid leukemia 1 0 1
Endometrial cancer 1 0 1
Carotid artery occlusion 1 0 1
Cerebrovascular accident 1 0 1
Dyspnea 1 0 1
SAE=serious adverse event; RENEW=Registry to Evaluate Novantrone Effects in
Worsening Multiple Sclerosis.
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curred in 5.3% and 5.6%, respectively; CHF was observed
in 10 (2%) patients overall. The decreased LVEF rates
reported here are comparable to those reported in the
French cohort and below the estimate reported by the
TTA Subcommittee. Conversely, the rate of CHF in RE-
NEW appears to be significantly higher (at least 5-fold)
compared with either TTA Subcommittee estimates or
the French cohort. It should be noted, however, that con-
firmation of CHF was not required in patients who experi-
enced signs or symptoms of CHF in the RENEW study.Post-hoc analyses of risk factors revealed that the cu-
mulative dose of Mitoxantrone is the primary risk factor
associated with cardiotoxicity in RENEW. There were
also consistent trends suggesting higher cardiac toxicity
in various sub-populations of patients, including: higher
age group, SPMS vs relapsing MS, longer disease dur-
ation, higher EDSS, use of concomitant immunosuppres-
sants and/or disease-modifying drugs. The independent
contribution of any one of these individual demographic
and disease characteristics to the risk of cardiotoxicity
needs to be interpreted with caution since they may be
interrelated and therefore coexist in the same patient (e.
g., an older subject will have had MS for a longer period
of time and may have accumulated a higher EDSS score,
leading to attempts by clinicians to add other drugs (i.e.,
immunosuppressants and/or disease-modifying drugs)).
The independent contribution of any of these factors to
a higher predisposition to risk of cardiac toxicity with
Mitoxantrone is unknown. Results also suggested that pre-
vious or concomitant treatment with oral Methotrexate
may also increase the risk of cardiotoxicity. The cardiovas-
cular risks associated with Methotrexate, however, have
yet to be established in patients with MS. The majority of
studies evaluating the impact of Methotrexate on cardio-
vascular events have focused on patients with rheumatoid
arthritis (RA), a systemic inflammatory disease associated
with an increased risk for morbidity and mortality from
cardiovascular disease [34]. Analysis in prospective [35],
observational [36], and retrospective [37] studies have sug-
gested that Methotrexate is cardioprotective in RA pa-
tients. Conversely, a longitudinal cohort study analyzing
data from 10,156 patients enrolled in the Consortium of
Rheumatology Researchers of North America Rheumatoid
Table 7 Deaths during the RENEW study
Count Age (years)/ Form Baseline Cause(s) Study phase Treatment Cumulative
gender of MS EDSS related? dose mg/m2
1 51/F SPMS 7 Pneumonia Treatment No 91.3
2 43/F SPMS 6 Decreased ejection fraction, Treatment Probable 96.8
cardiomyopathy, congestive heart
failure
3 50/F SPMS 8.5 Pulmonary embolism Treatment No 12.2
4 57/M SPMS 7 Road traffic accident Annual follow-up No 99.7
5 57/M SPMS 6 Prostate cancer Treatment No Unknown
6 49/M SPMS 6.5 Cerebrovascular accident, carotid Annual follow-up Possible 119.4
artery occlusion
7 57/M PRMS 7 Pulmonary edema Annual follow-up Unknown 109.5
8 55/F SPMS 6.5 Pulmonary embolism Annual follow-up No 67.7
9 51/F RRMS 4 Acute meningitis Treatment Possible 11.9
10 68/M SPMS 7.5 Respiratory failure Treatment No 11.1
11 37/F SPMS 9 Cardiopulmonary arrest Treatment No 18.4
12 44/F SPMS 7 Septic shock Treatment Possible 81.9
EDSS=Expanded Disability Status Scale; F=female; M=male; MS=multiple sclerosis; PRMS=progressive relapsing multiple sclerosis; RENEW=Registry to Evaluate
Novantrone Effects in Worsening Multiple Sclerosis; SPMS=secondary progressive multiple sclerosis.
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associated with a reduced risk of the primary composite
cardiovascular endpoint of incident non-fatal myocardial
infarction, non-fatal stroke or transient ischemic attack,
and cardiovascular-related death [38]. Controversy exists
on whether chronic MS is associated with cardiovascular
disease, with studies suggesting an association [39] and
others rejecting it [40,41]. The association between Metho-
trexate and cardiotoxicity observed in RENEW remains
speculative since analysis was post-hoc rather than pre-
specified. Furthermore, analysis with a larger cohort of
patients is also required to confirm the role of age and
Methotrexate therapy as predictive factors of cardiotoxicity.
Reports from Spanish cohorts have raised concerns
about the increased risk of leukemia in MS patients treated
with Mitoxantrone [17,28]. In the report by Pascual and
colleagues [28], investigators reported results from two
separate Spanish cohorts. In the first cohort treated with
Mitoxantrone [17,28], there were four cases of leukemia
among 142 patients with RRMS and SPMS. The four pa-
tients received total Mitoxantrone doses of 30, 60, 70, and
100 mg/m2. The cumulative incidence of leukemia was
2.82% (95% CI, 1.2–4.4) over a median follow-up time of
40 months since the start of treatment. In the second co-
hort containing 88 patients with MS [28], there were two
cases of leukemia in patients receiving 137 mg/m2 and
159 mg/m2 of Mitoxantrone, respectively. The cumulative
incidence of treatment-related leukemia in this cohort was
2.27% (95% CI, 1.1–3.4).
In contrast, analysis of leukemia among the French co-
hort identified two cases of Mitoxantrone-related leukemiato yield an incidence of 0.25%. The total cumulative dose of
Mitoxantrone was 70 mg/m2 in each case [33]. In addition,
retrospective analysis of data from 40 Italian MS centers
identified 30 cases of AML among 3,220 patients treated
with Mitoxantrone, yielding an incidence of 0.93%. Fur-
thermore, the authors reported that MS patients present-
ing with AML received a significantly higher dose of
Mitoxantrone compared with their non-AML counter-
parts (78.3 vs 64.7 mg/m2, respectively; p = 0.028) [26].
In the RENEW study, there were three reports of
Mitoxantrone-related leukemia (AML and CML) among
the 509 patients (incidence of 0.6%). The total cumulative
dose was 73.5 mg/m2, 107.3 mg/m2, and 97.1 mg/m2for
each case. These results are consistent with results from
the French and Italian cohort studies. RENEW results
are also consistent with a TTA Subcommittee analysis of
treatment-related leukemia among 4,076 patients combined
from 32 class III or IV evidence studies [25]. According to
TTA estimates, the incidence of treatment-related leukemia
in patients with MS is approximately 0.81%, with a NNH of
123. Again, the authors caution that this is a general ap-
proximation given the variability in time of follow-up
among the different studies, especially case reports.
The disparity in incidence rates between RENEW/
French cohort and the Spanish cohort is not completely
understood. It is worth noting, however, that the mean cu-
mulative dose was 87.7 mg/m2 when the 10 patients from
the respective cohorts are combined. Given the dose-
dependent data reported by the Italian group [26], it is
reasonable to speculate that the 10 patients from the com-
bined cohorts were at higher risk for developing
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dose. Genetic risk cannot be ruled out either.
The French cohort evaluated the reproductive safety
profile of Mitoxantrone in 317 women with MS starting
treatment at 45 years of age or younger [33]. Transient
amenorrhea was observed in 27% of women while per-
sistent amenorrhea was observed in 17.3% of women.
No persistent amenorrhea, however, was observed in
women treated before the age of 25. The likelihood of
experiencing persistent amenorrhea increased with age
in this cohort. In the RENEW trial, the incidence of
transient amenorrhea (4% during the treatment phase
and 1% during follow-up) was lower compared with the
French cohort. The incidence of persistent amenorrhea
was consistent between studies (22% during the treat-
ment phase and 5% during follow-up in RENEW). In the
RENEW cohort, women who at baseline reported irregu-
lar menses had a higher incidence (51%) of persistent
amenorrhea compared to women who reported regular
menses (22%), despite the fact that the mean cumulative
dose of Mitoxantrone was higher in the latter group.
These results indicate that women with menstrual ir-
regularity are at higher risk of developing persistent
amenorrhea while taking Mitoxantrone.
Conclusion
RENEW provides additional data on the long-term safety
of Mitoxantrone in patients with worsening MS. There
are limitations that must be considered when evaluating
this data. First, RENEW data are registry-based, and not
from a controlled trial. As a result, more than half of the
patients were lost during the 5-year planned follow-up.
Patient drop out, therefore, may lead to underestimation
of the incidence of cardiovascular events, leukemia, and
SAEs reported here. To ascertain whether there are
more cases of cardiovascular events or leukemia, a sec-
ond RENEW Study has been initiated to contact patients
who originally left RENEW for reasons other than death
or lost to follow-up. Another factor that may lead to
underestimation of Mitoxantrone-related SAEs includes
the protocol for evaluating SAE by relationship to study
drug. In RENEW, SAE by relationship to study drug was
determined by the local study investigator rather than an
independent review board. Lastly, there is also complex-
ity in data interpretation due to variability in physician
behaviour/use of Mitoxantrone (on-label vs off-label)
and variability in severity of patient disease when first
treated with Mitoxantrone.
Taking study limitations into consideration, the data
reported here demonstrate that, consistent with previous
reports, Mitoxantrone therapy in MS patients is associ-
ated with significant side effects, and that Mitoxantrone
cumulative dose exposure is clearly associated with car-
diac toxicity. Use of Mitoxantrone in worsening RRMS,transitional forms, and in patients no longer responding to
first-line therapies should be cautiously considered, and
prescribing physicians should: 1) stay on-label, 2) use the
lowest possible cumulative dose that achieves the desired
clinical effect and 3) vigilantly monitor patients for clinical,
cardiac, and neoplastic complications before every dose of
Mitoxantrone and annually following treatment.
Additional files
Additional file 1: Potential cardiac risk explanatory factors:
demographic, disease history, dosing (population: all treated subjects).
Additional file 2: Serious adverse events reported during the
treatment and annual follow-up phases of RENEW.
Additional file 3: Serious infection events by relationship to
Mitoxantrone during the treatment and follow-up phases of RENEW.
Competing interests
VMR declared that there is no conflict of interest. DRJ has received honoraria
for speaking and consulting with Bayer, Biogen Idec, Teva, EMD Serono,
Pfizer, Novartis, Genzyme, Roche, and Acorda. BWG has participated in
speaker’s bureaus and served as a consultant for Biogen Idec, Teva
Neuroscience, EMD Serono, Pfizer, Novartis, Genzyme, and Acorda. Excluding
Genzyme, BWG has also received grant/research support from the
aforementioned companies as well as ITN, Questcor, and Shire. No other
industry financial relationships exist. DB was an employee at EMD Serono
during the development of this manuscript. DB is currently an employee at
BDM Consulting, Inc and declares no other industry financial relationships.
FD is an employee of EMD Serono, receiving salary and employment
benefits from the company.
Authors’ contributions
VMR, DRJ, BWG and FD participated in the analysis and interpretation of
data. DB contributed to the acquisition of data and performed the statistical
analyses. All authors read and approved the final manuscript.
Acknowledgments
The authors wish to thank Randy Bennett and Daryl Dawson of EMD Serono,
Inc for their contributions to this manuscript. Molly VanZant and Erin
Hopkins of REGISTRAT-MAPI planned and conducted the statistical analysis.
Medical writing/editorial support was provided by Caroline Hoang, PhD of
ACUMED (New York, NY), and was funded by EMD Serono, Inc.
This study was sponsored by EMD Serono, Inc, a subsidiary of Merck KGaA,
Darmstadt, Germany.
Author details
1Baylor College of Medicine, Houston, TX, USA. 2Cornerstone Health Care,
Advance, NC, USA. 3Jacobs Neurological Institute, State University of New
York-University of Buffalo, Buffalo, NY, USA. 4EMD Serono Inc, Rockland, MA,
USA.
Received: 20 November 2012 Accepted: 1 July 2013
Published: 11 July 2013
References
1. Levine S, Saltzman A: Regional suppression, therapy after onset and
prevention of relapses in experimental allergic encephalomyelitis by
Mitoxantrone. J Neuroimmunol 1986, 13:175–181.
2. Lublin FD, Lavasa M, Viti C, Knobler RL: Suppression of acute and relapsing
experimental allergic encephalomyelitis with Mitoxantrone. Clin Immunol
Immunopathol 1987, 45:122–128.
3. Watson CM, Davison AN, Baker D, O’Neill JK, Turk JL: Suppression of
demyelination by Mitoxantrone. Int J Immunopharmacol 1991, 13:923–930.
4. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet
B, Berry I, Rolland Y, Froment JC, Cabanis E, Iba-Zizen MT, Gandon JM, Lai
HM, Moseley I, Sabouraud O: Therapeutic effect of Mitoxantrone
combined with methylprednisolone in multiple sclerosis: a randomised
Rivera et al. BMC Neurology 2013, 13:80 Page 11 of 11
http://www.biomedcentral.com/1471-2377/13/80multicentre study of active disease using MRI and clinical criteria.
J Neurol Neurosurg Psychiatry 1997, 62:112–118.
5. Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, Krapf
H, Zwingers T: Mitoxantrone in Multiple Sclerosis Study Group (MIMS):
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled,
double-blind, randomised, multicentre trial. Lancet 2002, 360:2018–2025.
6. Avasarala JR, Cross AH, Clifford DB, Singer BA, Siegel BA, Abbey EE: Rapid
onset Mitoxantrone-induced cardiotoxicity in secondary progressive
multiple sclerosis. Mult Scler 2003, 9:59–62.
7. De-Castro CS, Cartoni D, Millefiorini E, Funaro S, Gasperini C, Morino S,
Tallarico D, Beni S: Non-invasive assessment of mitoxantrone
cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol
1995, 35:627–632.
8. Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, Gonsette
RE, Butine MD, Goodkin DE: Cardiac adverse effects associated with
Mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002,
59:909–913.
9. Hamzehloo A, Etemadifar M: Mitoxantrone-induced cardiotoxicity in
patients with multiple sclerosis. Arch Iran Med 2006, 9:111–114.
10. Paul F, Dörr J, Würfel J, Vogel HP, Zipp F: Early Mitoxantrone-induced
cardiotoxicity in secondary progressive multiple sclerosis. J Neurol
Neurosurg Psychiatry 2007, 78:198–200.
11. Zingler VC, Nabauer M, Jahn K, Gross A, Hohlfeld R, Brandt T, Strupp M:
Assessment of potential cardiotoxic side effects of Mitoxantrone in
patients with multiple sclerosis. Eur Neurol 2005, 54:28–33.
12. Goffette S, van-Pesch V, Vanoverschelde JL, Morandini E, Sindic CJ: Severe
delayed heart failure in three multiple sclerosis patients previously
treated with Mitoxantrone. J Neurol 2005, 252:1217–1222.
13. Khatri BO, Wroblewski M, Kramer CJ, Dukic M, Poplar A, Anderson AJ:
Mitoxantrone in worsening secondary progressive multiple sclerosis: a
prospective, open-label study. CurrTher Res 2006, 67:55–65.
14. Ostberg A, Pittas F, V B: Use of low-dose Mitoxantrone to treat aggressive
multiple sclerosis: a single-centre open-label study using patient self-
assessment and clinical measures of multiple sclerosis status. Intern Med
J 2005, 35:382–387.
15. Buttinelli C, Clemenzi A, Borriello G, Denaro F, Pozzilli C, Fieschi C:
Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI
follow-up. Eur J Neurol 2007, 14:1281–1287.
16. Arruda WO, Montú MB, de-Oliveira MS, Ramina R: Acute myeloid leukaemia
induced by Mitoxantrone: case report. Arq Neuropsiquiatr 2005, 63:327–329.
17. Bosca I, Pascual AM, Casanova B, Coret F, Sanz MA: Four new cases of
therapy-related acute promyelocytic leukemia after Mitoxantrone.
Neurology 2008, 71:457–458.
18. Brassat D, Recher C, Waubant E, Le-Page E, Rigal-Huguet F, Laurent G, Edan G,
Clanet M: Therapy-related acute myeloblastic leukemia after Mitoxantrone
treatment in a patient with MS. Neurology 2002, 59:954–955.
19. Cattaneo C, Almici C, Borlenghi E, Motta M, Rossi G: A case of acute
promyelocytic leukaemia following Mitoxantrone treatment of multiple
sclerosis. Leukemia 2003, 17:985–986.
20. Delisse B, de-Seze J, Mackowiak A, N’Kendjuo JB, Verier A, Derepeer O,
Boisselier C, Devos P, Hautecoeur P, Vermersch P, G-SEP: Therapy related
acute myeloblastic leukaemia after Mitoxantrone treatment in a patient
with multiple sclerosis. Mult Scler 2004, 10:92.
21. Ellis R, Boggild M: Therapy-related acute leukaemia with Mitoxantrone:
what is the risk and can we minimise it? Mult Scler 2009, 15:505–508.
22. Ghalie RG, Mauch E, Edan G, Hartung HP, Gonsette RE, Eisenmann S,
Le-Page E, Butine MD, De-Goodkin DE: A study of therapy-related acute
leukaemia after Mitoxantrone therapy for multiple sclerosis. Mult Scler
2002, 8:441–445.
23. Heesen C, Bruegmann M, Gbdamosi J, Koch E, Mönch A, Buhmann C:
Therapy-related acute myelogenous leukaemia (t-AML) in a patient with
multiple sclerosis treated with Mitoxantrone. Mult Scler 2003, 9:213–214.
24. Ledda A, Caocci G, Spinicci G, Cocco E, Mamusa E, La Nasa G: Two new cases
of acute promyelocytic leukemia following Mitoxantrone treatment in
patients with multiple sclerosis. Leukemia 2006, 20:2217–2218.
25. Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW, Therapeutics and
Technology Assessment Subcommittee of the American Academy of
Neurology: Evidence Report: The efficacy and safety of Mitoxantrone
(Novantrone) in the treatment of multiple sclerosis: Report of the
Therapeutics and Technology Assessment Subcommittee of the
American Academy of Neurology. Neurology 2010, 74:1463–1470.26. Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I,
Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM,
Tojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L,
Ponzio M, Comi G, Italian Mitoxantrone Group: Acute myeloid leukemia in
Italian patients with multiple sclerosis treated with Mitoxantrone.
Neurology 2011, 77:1887–1895.
27. Novoselac AV, Reddy S, Sanmugarajah J: Acute promyelocytic leukemia in
a patient with multiple sclerosis following treatment with Mitoxantrone.
Leukemia 2004, 18:1561–1562.
28. Pascual AM, Téllez N, Boscá I, Mallada J, Belenguer A, Abellán I, Sempere AP,
Fernández P, Magraner MJ, Coret F, Sanz MA, Montalbán X, Casanova B:
Revision of the risk of secondary leukaemia after Mitoxantrone in
multiple sclerosis populations is required. Mult Scler 2009, 15:1303–1310.
29. Tanasescu R, Debouverie M, Pittion S, Anxionnat R, Vespignani H: Acute
myeloid leukaemia induced by Mitoxantrone in a multiple sclerosis
patient. J Neurol 2004, 251:762–763.
30. Vicari AM, Ciceri F, Folli F, Lanzi R, Colombo B, Comi G, Camba L: Acute
promyelocytic leukemia following Mitoxantrone as single agent for the
treatment of multiple sclerosis. Leukemia 1998, 12:441–442.
31. Voltz R, Starck M, Zingler V, Strupp M, Kolb HJ: Mitoxantrone therapy in
multiple sclerosis and acute leukaemia: a case report out of 644 treated
patients. Mult Scler 2004, 10:472–474.
32. Woo DA, Collins RH, Rossman HS, Stüve O, Frohman EM: Mitoxantrone-
associated leukemia in multiple sclerosis: case studies. Int J MS Care 2008,
10:41–46.
33. Le-Page E, Leray E, Edan G, French Mitoxantrone Safety Group: Long-term
safety profile of Mitoxantrone in a French cohort of 802 multiple
sclerosis patients: a 5-year prospective study. Mult Scler 2011, 17:867–875.
34. Myasoedova E, Gabriel SE: Cardiovascular disease in rheumatoid arthritis:
a step forward. Curr Opin Rheumatol 2010, 22:342–347.
35. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F: Methotrexate and
mortality in patients with rheumatoid arthritis: a prospective study.
Lancet 2002, 359:1173–1177.
36. Bernatsky S, Hudson M, Suissa S: Anti-rheumatic drug use and risk of
hospitalization for congestive heart failure in rheumatoid arthritis.
Rheumatology (Oxford) 2005, 44:677–680.
37. Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, David JM 3rd,
Roger VL, Therneau TM, Gabriel SE: The influence of rheumatoid arthritis
disease characteristics on heart failure. J Rheumatol 2011, 38:1601–1606.
38. Greenberg JD, Kremer JM, Curtis JR, CORRONA Investigators: Tumour
necrosis factor antagonist use and associated risk reduction of
cardiovascular events among patients with rheumatoid arthritis.
Ann Rheum Dis 2011, 70:576–582.
39. Jadidi E, Mohammadi M, Moradi T: High risk of cardiovascular diseases after
diagnosis of multiple sclerosis. Mult Scler 2013. Jan 30. [Epub ahead of print].
40. Fleming ST, Blake RL Jr: Patterns of comorbidity in elderly patients with
multiple sclerosis. J Clin Epidemiol 1994, 47:1127–1132.
41. Allen NB, Lichtman JH, Cohen HW, Fang J, Brass LM, Alderman MH:
Vascular disease among hospitalized multiple sclerosis patients.
Neuroepidemiology 2008, 30:234–238.
doi:10.1186/1471-2377-13-80
Cite this article as: Rivera et al.: Results from the 5-year, phase IV RENEW
(Registry to Evaluate Novantrone Effects in Worsening Multiple
Sclerosis) study. BMC Neurology 2013 13:80.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
